Last reviewed · How we verify
NCT06892054: PANSOTO
Sotorasib Combined With First-line Chemotherapy for Advanced Pancreatic Adenocarcinoma
Phase 2 trial testing Sotorasib, 960 mg, oral daily dose for 4 weeks (28 days) in Pancreatic Adenocarcinoma in 15 participants. Not yet recruiting.
30 June 2030
Quick facts
| Lead sponsor | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) |
|---|---|
| Phase | Phase 2 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 15 |
| Start date | 30 June 2025 |
| Primary completion | 30 June 2030 |
| Estimated completion | 30 June 2030 |
| Sites | 25 locations across France, Spain |
Drugs / interventions tested
- Sotorasib, 960 mg, oral daily dose for 4 weeks (28 days) — full drug profile →
Conditions studied
- Pancreatic Adenocarcinoma — all drugs for Pancreatic Adenocarcinoma →
Sponsor
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Who can join
18 and older, any sex, with Pancreatic Adenocarcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The main objective of this trial is to evaluate the safety and tolerability of sotorasib combined with first-line chemotherapy for advanced pancreatic adenocarcinoma harboring KRAS p.G12C mutation.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06892054
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Sotorasib, 960 mg, oral daily dose for 4 weeks (28 days)
Trials testing the same drug.
- NCT05400577 — Sotorasib in KRAS G12C Mutated, Resectable, Stage Ib-IIIA NSCLC · Phase 2 · withdrawn
Other recruiting trials for Pancreatic Adenocarcinoma
Currently open trials in the same condition.
- NCT07126158 — Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma · Phase 2 · recruiting
- NCT07488676 — A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors · Phase 1, PHASE2 · recruiting
- NCT07493421 — To Evaluate the Feasibility and Safety of Combining Surgery (Pancreatectomy and Cytoreduction) With HIPEC for Treating P · NA · recruiting
- NCT06896188 — 9-ING-41 Combined With Retifanlimab, Plus Modified FOLFIRINOX for Patients With Advanced Pancreatic Adenocarcinoma (RiLE · Phase 1 · recruiting
- NCT07090499 — A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors · Phase 1 · recruiting
Other Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) trials
Trials by the same sponsor.
- NCT06207656 — Study to Evaluate the Efficacy and Safety of Cetuximab in Combination with Encorafenib Plus Binimetinib As Induction Tre · Phase 2 · recruiting
- NCT05659914 — Olaparib and Durvalumab (MEDI4736) in Patients with Metastatic Pancreatic Cancer and DNA Damage Repair Genes Alterations · Phase 2 · active not recruiting
- NCT03635021 — Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Be · Phase 3 · active not recruiting
- NCT03279289 — Study to Assess the Efficacy and Safety of Treatment With FOLFIRI-aflibercept Compared to Initial Treatment With FOLFIRI · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06892054 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
- Last refreshed: 24 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06892054.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing